Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
J0207 Amifostine Ethyol 500 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan 1, 1998 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
C9083 Amivantamab-vmjw Rybrevant 10mg Immunotherapy Monoclonal Antibody EGFR,MET No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
S0170 Anastrozole Arimidex 1mg Hormonal Therapy Aromatase Inhibitor Yes 1995 Jan 1, 2002 In Use
NA Apalutamide Erleada 60mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2018 In Use
J8501 Aprepitant Emend 5 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 Jan 1, 2005 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
C9145 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 17, 2023 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2002 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 In Use
C9289 Asparaginase Erwinaze 1,000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Apr 4, 2012 Dec 31, 2014 No Longer Used
J9019 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Jan 1, 2013 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct 1, 2016 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.